GI
LGND icon

Gradient Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Gradient Investments’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed -$74 – 1840
2023
Q1 		$74 Sell
1
-12
-92% -$853 ﹤0.01% 1456
2022
Q4 		$868 Buy
13
+11
+550% +$715 ﹤0.01% 1220
2022
Q3 		$0 Buy
+2
New +$118 ﹤0.01% 1454

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Gradient Investments's LGND Position: Q2 2023 in Review

Gradient Investments sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 1 share — an estimated $74 sold.

Gradient Investments first reported a position in LGND in Q3 2022 and held it in 3 quarters. The position peaked at $868 in Q4 2022. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

  • Gradient Investments reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Gradient Investments sold 1 Ligand Pharmaceuticals share in Q2 2023, an estimated $74.
  • Gradient Investments first reported a position in Ligand Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Gradient Investments's Ligand Pharmaceuticals position peaked at $868 in Q4 2022.
  • 204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on Gradient Investments's 13F filing for Q2 2023, filed 11 Jul 2023.